CNS delivery of anti-CD52 antibodies modestly reduces disease severity in an animal model for multiple sclerosis

BACKGROUND AND AIMS: Alemtuzumab is a humanized monoclonal antibody that depletes CD52-bearing B and T lymphocytes. Clinical trials defined that systemic administration of alemtuzumab reduces disease severity in the relapsing–remitting phase of multiple sclerosis (MS). However, its efficacy in progr...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Ther Adv Chronic Dis
Main Authors: Bogie, Jeroen FJ, Grajchen, Elien, Wouters, Elien, Broux, Bieke, Stinissen, Piet, Van Wijmeersch, Bart, Hendriks, Jerome JA
Format: Artigo
Jezik:Inglês
Izdano: SAGE Publications 2020
Teme:
Original Research
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7443992/
https://ncbi.nlm.nih.gov/pubmed/32913622
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040622320947378
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki